title: Studies on type II collagen induced arthritis in mice.
abstract: A consistent and reproducible polyarthritis was induced in mice by immunizing them with type II collagen in Complete Freunds adjuvant (CFA) and Bacillus Calmette-Guerin (BCG) vaccine. Several inbred strains of mice were investigated for the ability to develop collagen induced arthritis (CIA). DBA/1 mice (H-2q) produced the highest incidence and the most severe arthritis of all the strains examined. Viable BCG vaccine was essential for the induction of a reproducible disease in this strain. The effects of some anti-inflammatory and anti-rheumatic compounds were examined on the developing and established lesions of CIA. These effects were determined by assessing the paw inflammation using a subjective scoring system and measuring foot weight. Furthermore, levels of serum amyloid P component (SAP) were also determined. Benoxaprofen, cyclophosphamide, indomethacin and prednisolone inhibited the paw inflammation in the developing disease whilst the anti-rheumatic compounds auranofin and D-penicillamine exacerbate the paw inflammation. Cyclophosphamide and prednisolone inhibited the established lesions but only prednisolone prevented the development of further lesions in the established disease. The SAP levels in the prednisolone treated group were also reduced. Auranofin treatment exacerbated the inflammation of both the established and the developing lesions in the same animal. D-penicillamine was inactive in the established disease.
mesh_terms: D000682:Amyloid / Q000097:blood; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives / Q000627:therapeutic use; D001500:BCG Vaccine; D003094:Collagen; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D007213:Indomethacin / Q000627:therapeutic use; D007249:Inflammation; D051379:Mice; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains; D011239:Prednisolone / Q000627:therapeutic use; D011422:Propionates / Q000627:therapeutic use; D000683:Serum Amyloid P-Component; D013045:Species Specificity
chemical_list: D000682:Amyloid; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001500:BCG Vaccine; D011422:Propionates; D000683:Serum Amyloid P-Component; C011677:benoxaprofen; D006051:Aurothioglucose; D001310:Auranofin; D003520:Cyclophosphamide; D003094:Collagen; D011239:Prednisolone; D007213:Indomethacin